Compare DIT & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIT | ENTX |
|---|---|---|
| Founded | 1981 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.2M | 62.6M |
| IPO Year | 1996 | 2015 |
| Metric | DIT | ENTX |
|---|---|---|
| Price | $83.26 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 546.0 | ★ 100.4K |
| Earning Date | 04-20-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $1,392,388,157.00 | $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.86 |
| Revenue Growth | ★ 5.30 | N/A |
| 52 Week Low | $78.00 | $0.91 |
| 52 Week High | $126.50 | $3.22 |
| Indicator | DIT | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 49.67 |
| Support Level | $80.10 | $1.17 |
| Resistance Level | $120.08 | $1.37 |
| Average True Range (ATR) | 1.46 | 0.09 |
| MACD | -0.19 | 0.00 |
| Stochastic Oscillator | 34.16 | 48.21 |
Amcon Distributing Co is engaged in the wholesale and retail distribution of consumer products such as cigarettes, tobacco, confectionery, health food, and others. It operates in two segments: Wholesale distribution segment distributing consumer products to the retail outlets including convenience stores, grocery stores, liquor stores, drug stores and tobacco shops in the Central, Rocky Mountain, and Southern regions of the United States; and the Retail health food segment is a specialty retailer of natural/organic groceries and dietary supplements throughout the Midwest and Florida. The company earns a majority of the revenue from the Wholesale distribution segment.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.